The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21588
Abstract: e21588Background: Immune checkpoint inhibitors are standard of care for most patients (pts) with MM, yet only a minority has durable disease control. CTX has limited activity when used first-line, ... read more here.
Keywords: melanoma multicenter; utility chemotherapy; immunotherapy failure; metastatic melanoma ... See more keywords